Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15762045 | 0.92 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL10201708 | 0.90 | CYP2D6 (0.53) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL10201852 | 0.90 | CYP2D6 (0.60) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL10201854 | 0.85 | CYP2D6 (0.54) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL26455582 | 0.78 | TSHR (0.36) | CYP2D6TSHRCYP1A2 | |
| SCHEMBL18418138 | 0.77 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL16261385 | 0.76 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2CYP3A4TSHRCYP2C9 | |
| SCHEMBL9917289 | 0.76 | NPSR1 (0.41) | CYP2D6SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL12683692 | 0.76 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2CYP3A4TSHRCYP2C9 | |
| SCHEMBL22256988 | 0.75 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP3A4TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | CYP2D6 4437/4885SMN1; SMN2 4588/4885CYP3A4 3783/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | CYP2D6 1969/4885SMN1; SMN2 3221/4885CYP3A4 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.